European Commission Approves Mosunetuzumab for Patients with R/R Follicular Lymphoma - Targeted Oncology
The European Commission has granted a conditional marketing authorization to mosunetuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 prior systemic therapies
Conditional marketing authorization has been granted to the CD20xCD3 T-cell engaging bispecific antibody mosunetuzumab (Lunsumio) by the European Commission for the treatment of adult patients with r… [+6886 chars]
Read More
Other Stories in Business
- Saudi petrochemical group SABIC reports 62% plunge in profits
- Staking Litecoin Cash: Quick and Simple Tips for Beginners to Start Earning
- IDFC First Bank stocks: Buy IDFC First Bank, target price Rs 104: Axis Securities
- Everyone’s eyeing hydrogen therapy. But does it work?
- Bajaj Finance Q4 Results Review - Staring At A Weaker Year Ahead; Downgrade To Neutral: Motilal Oswal
- What Led To RBI's Restrictions On Kotak Mahindra Bank
- What Led To RBI's Restrictions On Kotak Mahindra Bank
- Ukraine says it caught a man trying to escape the country by paddling on an inflatable mattress to Moldova
- Amazon Canada Deals: Save 50% on Monocular Telescope + 71% on Bluetooth Speaker Wireless with Promo Code & Coupon + 44% on Women Body Shaper + 40% on Apple Watch Charger - Hot Canada Deals
